Clinical Management Guidelines for Germline Predisposition to Myeloid Neoplasms

This guide outlines clinical management guidelines for patients with a positive test result indicating a germline predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It references the Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults as the primary source for medical management recommendations, noting that U.S. consensus practice guidelines are not available. The document emphasizes the importance of clinical correlation with the patient's medical history and genetic testing results, which inform management decisions but do not serve as formal recommendations. It details various screening and surgical considerations, including the frequency of complete blood counts and bone marrow biopsies. The guide also discusses the potential for allogenic hematopoietic stem cell transplant and the need for individualized management plans in consultation with healthcare providers. Additionally, it addresses the implications of pathogenic variants in the CEBPA gene and the associated cancer risks, recommending family testing and genetic counseling as part of the management strategy.